Details for New Drug Application (NDA): 209569
✉ Email this page to a colleague
The generic ingredient in TISSUEBLUE is brilliant blue g. One supplier is listed for this compound. Additional details are available on the brilliant blue g profile page.
Summary for 209569
| Tradename: | TISSUEBLUE |
| Applicant: | Dutch Ophthalmic |
| Ingredient: | brilliant blue g |
| Patents: | 0 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 209569
Generic Entry Date for 209569*:
Constraining patent/regulatory exclusivity:
INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM) Dosage:
SOLUTION;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 209569
| Mechanism of Action | Dyes |
Suppliers and Packaging for NDA: 209569
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TISSUEBLUE | brilliant blue g | SOLUTION;OPHTHALMIC | 209569 | NDA | D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. | 68803-722 | 68803-722-05 | 10 POUCH in 1 CARTON (68803-722-05) / 1 SYRINGE, GLASS in 1 POUCH / .5 mL in 1 SYRINGE, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;OPHTHALMIC | Strength | 0.025% | ||||
| Approval Date: | Dec 20, 2019 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Dec 20, 2026 | ||||||||
| Regulatory Exclusivity Use: | INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM) | ||||||||
Complete Access Available with Subscription
